Navigation Links
Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus
Date:11/9/2010

for at least 5 and 28 days, respectively, prior to first study drug infusion. Primary endpoint was responder rate on a combined index of clinical disease activity at week 12 (defined as reduction of all baseline (BL) BILAG 2004 A to B/C/D and BL BILAG B to C/D, no BILAG worsening in other organ systems, and no deterioration in SLEDAI or physician global assessment [VAS]), with no CS, IS and antimalarials increase over BL dose. The study was not powered to detect statistical differences between treatment arms.

By week 12 (see table) combined responder index rates were higher in all epratuzumab groups than in the placebo group, reaching statistical significance in the epratuzumab 600mg weekly group (2400mg cumulative) and the combined group of all 74 patients who received a cumulative dose of 2400mg (600mg weekly and 1200mg every other week).Dose regimenPBO
(n=38)Emab cd
200mgEmab cd
800mgEmab cd 2400mgEmab cd
3600mg100mg
EOW
(n=39)400mg
EOW
(n=38)600mg
weekly
(n=37(a))1200mg
EOW
(n=37)Combined
group
(n=74)1800mg
EOW
(n=38)Responders n (%)

8 (21.1)

12 (30.8)

10 (26.3)

17 (45.9)

15 (40.5)

32 (43.2)

9 (23.7)Odds ratio1.7

(0.6-4.7)

1.3

(0.5-3.9)

3.2

(1.1-8.8)

P=0.03(b)

2.6

(0.9-7.1)

P=0.07 (b)

2.9

(1.2-7.1) p=0.02 (b)

1.2

(0.4-3.4)Table - Combined responder index, week 12 (ITT population)Emab = epratuzumab

(a) 2 patients randomized but never received drug

(b) p values not adjusted for multiple comparisonsAdditionally, by Week 12, more patients in the epratuzumab 600mg weekly group, compared with placebo, had an improvement from BILAG A/B to BILAG D in the 6 body systems, indicating no
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Pa. , July 10, 2014 ... Moberg Research,s (Moberg) medical device manufacturing facility. Rep. ... Moberg,s advanced neurological monitors facilitate cutting-edge research in ... Rep. Kennedy and mental health advocate, Garen ... organization dedicated to fostering fundamental changes that will ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical ... today announced it has entered into an agreement with ... operates as EMD Serono in the United ... to collaborate with Merck KGaA,s biopharmaceutical division on the ... an undisclosed target using Ventana,s proprietary diagnostic assays. In ...
(Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... today,announced that the United States Food and Drug ... for the treatment of pulmonary,arterial hypertension (PAH). Terguride ... Phase II trial in Europe., "The FDA,s ... PAH,encourages and strengthens our development program by offering ...
... Tigris Pharmaceuticals,Inc. announced today the execution of a ... Cancer Institute (NCI) to,collaborate on clinical and preclinical ... development. AFP-464 is converted to,metabolites which bind covalently ... This is part of a four-year CRADA encompassing ...
Cached Medicine Technology:Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3
(Date:7/12/2014)... Albany, NY (PRWEB) July 12, 2014 ... to 2020 - New and Late-Stage Four-Factor PCCs ... in-depth analysis of the critical care market in ... and Canada. The report provides an estimation of ... to 2020. It covers critical care indications that ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As reported in ... Institute of Standards and Technology), the June 25th, 2014 Supreme ... electronic discovery world. It was also met with ... depending on whether it was seen from an individual privacy ... much is fact, there is now precedent which will require ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Dubai is ... basketball legend is heading to the UAE. The ... champion will be in the UAE from 28-31 October ... in support of diabetes awareness. The event is being ... marketing and event management company based in Dubai. The ...
(Date:7/12/2014)... 12, 2014 Praeclarus Press ... as a valuable new resource for women in need ... American women work away from their children. Today’s mothers ... benefits of breastfeeding, but often feel unsupported when it ... babies. With its evidence-based insights, and written by Nancy ...
(Date:7/12/2014)... July 12, 2014 Restore My Vision ... and Samantha Pearson, a couple boasting very impressive credentials ... Restore My Vision Today as a way to help ... have become in their respective patients’ treatments . ... to a “secret” trove of pertinent information relevant to ...
Breaking Medicine News(10 mins):Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3
... Antibiotic resistance is one of the biggest problems worldwide. ... be developed to fight these new antibiotic resistant infections. ... at Colney in Norfolk say they have used natural ... infections. Researchers said the discovery would allow scientists race ...
... used for treating obstructive sleep apnea patients, by making them ... resolving heart abnormalities, says Belgium physicians. // ,OSA ... ,"Not only are the shape and size ... was dilated and the heart muscle on the left side ...
... has been long regarded to be a chronic and unremitting ... temporary or short-lived condition // from which affected individuals can ... the same thing about alcohol. But now I think that ... what compulsive gambling is - for some people it is ...
... the NHS Heath Scotland, has had its lines choked with ... in Scotland since Sunday, last. // The line which ... fold increase of almost 450 calls a day, post ban ... flow of calls. This is a shot in the arm ...
... of the European Commission would be targeted towards controlling ... and malaria // that are haunting the Asian region. ... and TB through External Action' would be launched neat ... aimed at reducing the financial constraints that prevent the ...
... syndrome (PTSD) is a disabiling anxiety disorder, which was ... World War I, as soldier's heart and shell shock ... who are affected by cancer and their families as ... PTSD affects about 10 percent of those exposed to ...
Cached Medicine News:Health News:Compulsive Gambling Not A Chronic Addiction Always: Research 2Health News:Control And Prevention Of Three Diseases To Be Discussed: European Commission 2Health News:New Therapy For Treating Post-Traumatic Stress Syndrome 2
... to over 2,000 medical clinics nation wide, ... in mind, ChartingPlus relies heavily on a ... to improve documentation quality and increase productivity ... medical content is specific to your medical ...
... EncounterPRO Electronic Health Record ... System (WfMS) Specialties that ... and Immunology, Cardiology, Dermatology, ... Medicine, Neurology, Neurosurgery, Obstetrics ...
MediNotes e is an EMR design which utilizes a "tab concept for navigation. MediNotes e can display multiple patients, encounter notes, workflow items, patient flow, messages, alerts, and more, all in...
... Medical Record Software Interface ... Interface with programs, populates ... custom reports. Accumedics Electronic ... is Microsoft compatible allowing ...
Medicine Products: